Bristol Myers Squibb (BMY) Short-term Investments (2016 - 2025)
Historic Short-term Investments for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $464.0 million.
- Bristol Myers Squibb's Short-term Investments fell 955.17% to $464.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $464.0 million, marking a year-over-year decrease of 955.17%. This contributed to the annual value of $464.0 million for FY2025, which is 955.17% down from last year.
- According to the latest figures from Q4 2025, Bristol Myers Squibb's Short-term Investments is $464.0 million, which was down 955.17% from $776.0 million recorded in Q3 2025.
- Bristol Myers Squibb's 5-year Short-term Investments high stood at $3.0 billion for Q4 2021, and its period low was $130.0 million during Q4 2022.
- In the last 5 years, Bristol Myers Squibb's Short-term Investments had a median value of $796.0 million in 2023 and averaged $1.1 billion.
- In the last 5 years, Bristol Myers Squibb's Short-term Investments crashed by 9564.78% in 2022 and then skyrocketed by 52769.23% in 2023.
- Over the past 5 years, Bristol Myers Squibb's Short-term Investments (Quarter) stood at $3.0 billion in 2021, then plummeted by 95.65% to $130.0 million in 2022, then soared by 527.69% to $816.0 million in 2023, then crashed by 37.13% to $513.0 million in 2024, then fell by 9.55% to $464.0 million in 2025.
- Its last three reported values are $464.0 million in Q4 2025, $776.0 million for Q3 2025, and $1.0 billion during Q2 2025.